Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.52 |
| ▸ | TUBB | P07437 | 3/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180121 | 0.86 | CA2 (0.50) | PTGS2HTR2AHTR2CHTR2BTUBB4A | |
| SCHEMBL892587 | 0.82 | HTR2A (0.64) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL8910416 | 0.80 | PTGS2 (0.70) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL4464142 | 0.80 | HTR2A (0.75) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL2002599 | 0.79 | AKR1B1 (0.52) | CYP3A4MAPTCA9KDM4EMEN1 | |
| SCHEMBL11377273 | 0.79 | CA2 (0.40) | PTGS2HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL900845 | 0.79 | HTR2A (0.60) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL7956528 | 0.79 | PTGS2 (0.55) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL722969 | 0.78 | PTGS2 (0.67) | PTGS2HTR2AHTR2CHTR2BACHE | |
| SCHEMBL30374 | 0.78 | PTGS2 (1.00) | PTGS2HTR2AHTR2CHTR2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518750-B | Carbazole amino alcohol compound, preparation method thereof and application of carbazole amino alcohol compound in resisting parasitic diseases | 中国疾病预防控制中心寄生虫病预防控制所 | 2021-06-01 | — | — | CN | claimed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | THE BURNHAM INSTITUTE (US) | 2009-02-12 | — | — | US | claimed |
| EP-1227859-B1 | NEUROPHILIN LIGANDS FOR TREATING OCULAR CONDITIONS | ALCON INC (CH) | 2006-08-09 | — | — | EP | claimed |
| US-6943187-B2 | Pyrrolidine derivative hair growth compositions and uses | GPI NIL HOLDINGS, INC. (US) | 2005-09-13 | — | — | US | claimed |
| US-6818643-B1 | 3,9-DIAZABICYCLO(3.3.1)NONAN-2-ONE DERIVATIVES; PEPTIDYL-PROLYL ISOMERASE (PPIASE OR ROTAMASE) INHIBITORS; NEUROPROTECTIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-16 | — | — | US | claimed |
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | AMGEN INC. | 2004-09-23 | — | — | US | claimed |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | GPI NIL HOLDINGS, INC. (US) | 2004-03-11 | — | — | US | claimed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | claimed |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | GLIAMED, INC. | 2002-12-26 | — | — | US | claimed |
| EP-0171217-B1 | FUSED-RING HETEROCYCLIC COMPOUNDS A PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SANKYO COMPANY LIMITED (JP) | 1989-05-03 | — | — | EP | claimed |
| EP-0251194-A1 | Use of carbocyclic and heterocyclic condensed dihydropyridines for the preparation of cardioprotective remedies and heterocyclic and carbocyclic condensed dihydropyridines and methods and intermediates for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1988-01-07 | — | — | EP | claimed |
| US-4716162-A | BRAIN FUNCTION | SANKYO COMPANY, LIMITED (JP) | 1987-12-29 | — | — | US | claimed |
| EP-0191025-A1 | N-6 AND 5'-N SUBSTITUTED CARBOXAMIDOADENOSINE DERIVATIVES AS CARDIAC VASODILATORS AND ANTIHYPERTENSIVE AGENTS, AND PROCESS FOR MAKING SAID COMPOUNDS. | NELSON RES & DEV (US) | 1986-08-20 | — | — | EP | claimed |
| US-4584300-A | Platelet anti-aggregative- and calcium antagonistic -1,4-benzothiazin-3-one derivatives, compositions, and methods of use therefor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1986-04-22 | — | — | US | claimed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | claimed |
| WO-1986000310-A1 | N-6 AND 5'-N SUBSTITUTED CARBOXAMIDOADENOSINE DERIVATIVES AS CARDIAC VASODILATORS AND ANTIHYPERTENSIVE AGENTS, AND PROCESS FOR MAKING SAID COMPOUNDS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1986-01-16 | — | — | WO | claimed |
| US-4479949-A | ANTICOAGULANTS, ANTIARRHYTHMIA AGENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | claimed |
| EP-0116368-A1 | Benzothiazine derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1984-08-22 | — | — | EP | claimed |
| US-4024156-A | Thiophene ethanolamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186098-A1 | Method for preventing and treating hearing loss using sensorineurotrophic compounds | GAP43, CHAT, MYOC | PTGS2 804/4885HTR2A 1642/4885HTR2C 2040/4885 |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | PTGS2 440/4885HTR2A 2436/4885HTR2C 2253/4885 |
| US-20040049046-A1 | Small molecule inhibitors of rotamase enzyme activity | FKBP8, FKBP14, PREP | PTGS2 2041/4885HTR2A 3809/4885HTR2C 3943/4885 |
| US-20020198250-A1 | Pyrrolidine derivative hair growth compositions and uses | MKI67, PLOD2, HDGF | PTGS2 170/4885HTR2A 1460/4885HTR2C 1309/4885 |
| US-20090043099-A1 | Methods and compositions for derepression of IAP-inhibited caspase | BIRC5, API5, BIRC3 | PTGS2 1555/4885HTR2A 3132/4885HTR2C 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.